Updates

  • COVID-19 Clinical Task Force: Revised COVID-19 precautions take effect on Sept. 29, 2022

    As a result of the high levels of vaccine- and infection-induced immunity and the availability of effective treatments and prevention tools, along with the local alert designation of GREEN (low COVID risk) per the CDC data tracker, new revised COVID-19 recommendations will be in effect beginning Sept. 29. The changes are detailed in this latest message from the COVID-19 Task Force. This message is intended for UTMB employees, who must be logged onto the UTMB network to access the full text. Thank you.

  • Woman with face surgical mask getting arm swabbed

    El nuevo refuerzo de la vacuna bivalente

    Un nuevo refuerzo de la vacuna contra el COVID, diseñado para proteger contra las variantes actualmente dominantes BA.4/BA.5 esta disponible en UTMB.

  • Woman with face surgical mask getting arm swabbed

    New bivalent COVID vaccine booster

    A new COVID booster—designed to protect against the now-dominant BA.4/BA.5 strains will be available at UTMB Health starting Sept. 13. Learn about the new booster and who qualifies for it.

  • Sept. 6, 2022: COVID-19 Clinical Task Force updates visitation, social distancing and masking requirements

    Due to the declining rates of COVID-19 infections in our region, modifications have been made to the UTMB social distancing and masking requirements and visitation policy, effective September 7, 2022. The changes are detailed in this latest message from the COVID-19 Task Force. This message is intended for UTMB employees, who must be logged onto the UTMB network to access the full text. Thank you.

  • Two female students studying

    Novavax's COVID-19 Vaccine

    The U.S. Centers for Disease Control and Prevention recently approved Novavax’s COVID-19 vaccine for emergency use in adolescents ages 12 through 17.

  • COVID-19 update on the current wave, test-to-treat program and new vaccination option

    The UTMB COVID-19 Clinical Task Force shared updates on high test positivity rates among patients tested at UTMB, information on the successful COVID-19 test-to-treat program, and the new Novavax vaccine, an effective option for those reluctant or unable to get mRNA vaccines.

  • Vaccines available for children ages 6 months to 5 years

    Many parents, caregivers and clinicians have been waiting for a COVID-19 vaccine for younger children. Now that the CDC has approved the vaccine for children ages 6 months to 5 years, UTMB will begin offering the vaccine at our pediatric clinics beginning Monday, June 27.

  • Vaccines available for ages 6 months to 5 years

    Moderna and Pfizer-BioNTech COVID-19 Vaccines have now been authorized for children down to 6 months of age. On June 18, CDC endorsed that all children 6 months through 5 years of age should receive a COVID-19 vaccine.

  • June 23, 2022: Changes in testing policies for procedures, hospital admissions

    During the past few weeks, we have noted a rapid increase in COVID-19 test positivity in our community—now at 30%—and a gradually increasing inpatient census. As a result of these recent developments, changes in COVID-19 testing policies are being made...

  • Clinical Task Force: Updated COVID safety measures to take effect on June 7

    Due to a continued increase in COVID infections in the community this week (test positivity of >20%) together with a modest increase in COVID-related hospitalizations and rising infection among employees and students, new COVID precautions are being implemented effective June 7, 2022.

  • COVID-19 Clinical Task Force: Modifications to precautions due to increasing number of infections

    The rate of COVID infection has continued to increase in our region as well as among our patients and UTMB workforce. Although rates of severe infection and hospitalization due to COVID remain stable and low, caution is advised to keep our employees and patients safe from COVID infection during this current wave. The following COVID precautions are effective immediately. If the rates of COVID admissions and infections among our workforce increase further, additional precautions may be implemented.

  • Vaccination Task Force: CDC recommends FDA-approved single-dose booster for children ages 5-11

    On May 17, 2022, the U.S. Food and Drug Administration authorized the use of a single booster dose of the Pfizer-BioNTech COVID-19 Vaccine for children 5 through 11 years of age at least five months after completing a primary series with the Pfizer-BioNTech COVID-19 vaccine. (See the FDA announcement.) The Centers for Disease Control and Prevention approved the booster for this age group on May 19, 2022. CDC now recommends that children ages 5 through 11 years should receive a booster shot 5 months after their initial Pfizer-BioNTech vaccination series. (See the CDC announcement.)

  • FDA has approved single-dose booster for children ages 5-11

    A single booster dose of the Pfizer-BioNTech COVID-19 Vaccine has been approved for children 5 through 11 years of age, at least five months after completing a primary series with the Pfizer-BioNTech COVID-19 vaccine

  • Clinical Task Force: An Update on COVID-19—May 12, 2022

    There has been a modest increase in the COVID-19 positivity rate in our community, which has ranged from 6% to 11% in the past week. While the COVID-19 hospitalization rate has increased only slightly, it may increase further over the next two to three weeks. Currently, UTMB is not planning any immediate changes to our COVID-19 precautions. However, if COVID-19 positivity and hospitalization rates increase, changes in precautions may be necessary.

  • COVID-19 Vaccine Task Force: Revised masking guidelines effective immediately—April 22, 2022

    As a result of the continued low rates of COVID-19 infection in our community and among UTMB faculty, staff and students—as well as very low hospitalization rates—the following modifications to the masking policy will be implemented effective immediately, April 22, 2022. (Please note that we will continue to monitor infection and hospitalization rates in our region; therefore, these policies are subject to change on short notice, based on the most current data).